Comparative Hepatology Template
Write in a clean editor, then format for Comparative Hepatology in one click — DocuGuru applies the official BMC (BioMed Central) template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Comparative Hepatology format
Comparative Hepatology is a peer-reviewed journal published by BMC (BioMed Central), covering Liver physiology and pathology, Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation.
| Publisher | BMC (BioMed Central) |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Comparative Hepatology. 2023;12(3):45–58.
Formats any DOI in Comparative Hepatology style. No sign-up. |
| Publishes research in | Liver physiology and pathology Liver Disease Diagnosis and Treatment Liver Disease and Transplantation Organ Transplantation Techniques and Outcomes Hepatitis C virus research |
| ISSN | 1476-5926 |
| h-index | 36 |
| i10-index | 96 |
| Total citations | 5,664 |
| Top institutions publishing here | Akita University |
| Journal website | comparative-hepatology.biomedcentral.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Comparative Hepatology per year
Citation impact of Comparative Hepatology by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Comparative Hepatology
BACKGROUND: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a panel of biomarkers (SteatoTest), with sufficient predictive values, for the non-invasive diagnosis of steatosis in patients with or without chronic liver disease. Biomarkers and panels were assessed in a training group of consecutive patients with…
SUMMARY: BACKGROUND: Recent studies strongly suggest that due to the limitations and risks of biopsy, as well as the improvement of the diagnostic accuracy of biochemical markers, liver biopsy should no longer be considered mandatory in patients with chronic hepatitis C. In 2001, FibroTest ActiTest (FT-AT), a panel of biochemical markers, was found to have…
BACKGROUND: In patients with chronic hepatitis C virus, liver biopsy is the gold standard for assessing liver disease stage; nevertheless, it is prone to complications, some of them serious. Non-invasive methods have been proposed as surrogate markers for liver fibrosis. It was shown that serum hyaluronic acid (HA) level increases with the development for liver…